Advertisement
Advertisement
DFTX
Definium Therapeutics, Inc. Common Shares
28.34
USDSponsored
-1.14
-3.87%
Nov 20, 15:59 UTC -5
Closed
After-Market
28.33
-0.01
-0.05%
Definium Therapeutics, Inc. Common Shares (DFTX) Earnings
DFTX Earnings Reports
Positive Surprise Ratio
DFTX beat 1 of 5 last estimates.
20%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.52
Implied change from Q3 26 (Revenue/ EPS)
--
/+40.54%
Implied change from Q4 25 (Revenue/ EPS)
--
/+4.00%
Definium Therapeutics, Inc. Common Shares earnings per share and revenue
On Nov 09, 2026, DFTX reported earnings of -0.37 USD per share (EPS) for Q3 26, beating the estimate of -0.56 USD, resulting in a 34.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.12% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an increase of 40.54% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Definium Therapeutics, Inc. Common Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Definium Therapeutics, Inc. Common Shares reported EPS of -$0.37, beating estimates by 34.89%, and revenue of $0.00, 0% as expectations.
How did the market react to Definium Therapeutics, Inc. Common Shares's Q3 2026 earnings?
The stock price moved down -2.12%, changed from $35.39 before the earnings release to $34.64 the day after.
When is Definium Therapeutics, Inc. Common Shares expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Definium Therapeutics, Inc. Common Shares's next earnings report?
Based on --
analysts, Definium Therapeutics, Inc. Common Shares is expected to report EPS of -$0.52 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.